Evidence map›Paper›PMID 39487168›Full record

ArticleScientific reports2024

A DNA base-specific sequence interposed between CRX and NRL contributes to RHODOPSIN expression.

Rosa Maritato, Alessia Medugno, Emanuela D'Andretta, Giulia De Riso, Mariangela Lupo, Salvatore Botta, Elena Marrocco, Mario Renda, Martina Sofia, Claudio Mussolino and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rosa MaritatoDepartment of Translational Medicine, University of Naples Federico II, Naples, Italy.
Alessia MedugnoDepartment of Translational Medicine, University of Naples Federico II, Naples, Italy.
Emanuela D'AndrettaDepartment of Translational Medicine, University of Naples Federico II, Naples, Italy.
Giulia De RisoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Mariangela LupoTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
Salvatore BottaDepartment of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.
Elena MarroccoTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
Mario RendaTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
Martina SofiaTelethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
Claudio MussolinoMedical Center, University of Freiburg, Freiburg, Germany.
Maria Laura BacciDepartment of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
Enrico Maria SuraceDepartment of Translational Medicine, University of Naples Federico II, Naples, Italy. enricomaria.surace@unina.it.ORCID 0000-0002-2975-942X

Funding

European Research Council/ERC grant 311682European Research Council/ERC grant, ERC proof-of concept (ERC-POC) 813223Missione 4 - Center for Gene Therapy and Drugs based on RNA Technology- WP3.5 Stroke and other brain diseases, WP 3.5.7 E63C22000940007Prin MUR 2022LBZSTR
6 · The paper itself

Abstract

Gene expression emerges from DNA sequences through the interaction of transcription factors (TFs) with DNA cis-regulatory sequences. In eukaryotes, TFs bind to transcription factor binding sites (TFBSs) with differential affinities, enabling cell-specific gene expression. In this view, DNA enables TF binding along a continuum ranging from low to high affinity depending on its sequence composition; however, it is not known whether evolution has entailed a further level of entanglement between DNA-protein interaction. Here we found that the composition and length (22 bp) of the DNA sequence interposed between the CRX and NRL retinal TFs in the proximal promoter of RHODOPSIN (RHO) largely controls the expression levels of RHO. Mutagenesis of CRX-NRL DNA linking sequences (here termed "DNA-linker") results in uncorrelated gene expression variation. In contrast, mutual exchange of naturally occurring divergent human and mouse Rho cis-regulatory elements conferred similar yet species-specific Rho expression levels. Two orthogonal DNA-binding proteins targeted to the DNA-linker either activate or repress the expression of Rho depending on the DNA-linker orientation relative to the CRX and NRL binding sites. These results argue that, in this instance, DNA itself contributes to CRX and NRL activities through a code based on specific base sequences of a defined length, ultimately determining optimal RHO expression levels.

Indexed as

DNARhodopsinTrans-ActivatorsAnimalsBase SequenceBinding SitesGene Expression RegulationHomeodomain ProteinsHumansMicePromoter Regions, GeneticProtein BindingRegulatory Sequences, Nucleic Acidcone rod homeobox proteinDNAHomeodomain ProteinsRhodopsinTrans-Activators

Identifiers

PMID39487168
PMCPMC11530525

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.